In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299

Ugur Aytac, Kathryn S. McKee, Fernando Cabanillas, Linus Ho, Christopher Neumann, James L. Abbruzzese, Gordon B. Mills, Ruth LaPushin, Nam H. Dang, L. Clifton Stephens, Kei Ohnuma, Chikao Morimoto

    Research output: Contribution to journalArticle

    68 Scopus citations

    Abstract

    CD26 is a Mr 110,000 surface glycoprotein with diverse functional properties, including having a potentially significant role in tumor development, and antibodies to CD26 mediate pleomorphic cellular functions. In this report, we show that binding of soluble anti-CD26 monoclonal Ab 1F7 inhibits the growth of the human CD30+ anaplastic large cell T-cell lymphoma cell line Karpas 299 in both in vitro and in vivo experiments. In vitro experiments show that 1F7 induces cell cycle arrest at the G1-S checkpoint, associated with enhanced p21 expression that is dependent on de novo protein synthesis. Furthermore, experiments with a severe combined immunodeficient mouse tumor model demonstrate that 1F7 treatment significantly enhances survival of tumor-bearing mice by inhibiting tumor formation. Our data therefore suggest that anti-CD26 treatment may have potential clinical use for CD26+ hematological malignancies.

    Original languageEnglish (US)
    Pages (from-to)2031-2040
    Number of pages10
    JournalClinical Cancer Research
    Volume7
    Issue number7
    StatePublished - Jan 1 2001

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299'. Together they form a unique fingerprint.

  • Cite this

    Aytac, U., McKee, K. S., Cabanillas, F., Ho, L., Neumann, C., Abbruzzese, J. L., Mills, G. B., LaPushin, R., Dang, N. H., Stephens, L. C., Ohnuma, K., & Morimoto, C. (2001). In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clinical Cancer Research, 7(7), 2031-2040.